KSR staff publications

2019

Lang SH, Swift SL, White H, Misso K, Kleijnen J, Quek RGW. A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol 2019;Epub ahead of print. Full text.

 

Lang S, Swift S, Duffy S, Kleijnen J. Taking account of tumour heterogeneity in systematic reviews. Paper presented at EBMLive 2019; 15-17 Jul 2019; Oxford. BMJ Evidence-Based Medicine 2019;24(Suppl 1):A44. Poster.

 

Armstrong N, Ryder S, Forbes C, Ross J, Quek RGW. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol 2019;11:543-61. Full text.

 

van den Houten MML, Hageman D, Gommans LNM, Kleijnen J, Scheltinga MRM, Teijink JAW. The effect of supervised exercise, home based exercise and endovascular revascularisation on physical activity in patients with intermittent claudication: a network meta-analysis. Eur J Vasc Endovasc Surg 2019;[Epub ahead of print]. Abstract.

 

van Laake-Geelen CCM, Smeets RJEM, Quadflieg SPAB, Kleijnen J, Verbunt JA. The effect of exercise therapy combined with psychological therapy on physical activity and quality of life in patients with painful diabetic neuropathy: a systematic review. Scand J Pain 2019;[Epub ahead of print]. Abstract.

 

Ryder S, Fox K, Rane P, Armstrong N, Wei C-Y, Deshpande S, Stirk L, Qian Y, Kleijnen J. A systematic review of direct cardiovascular event costs: an international perspective. PharmacoEcon 2019;Epub ahead of print. Abstract.

 

Grimm SE, Fayter D, Ramaekers BLT, Petersohn S, Riemsma R, Armstrong N, Pouwels X, Witlox W, Noake C, Worthy G, Kleijnen J, Joore MA. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: an Evidence Review Group perspective of a NICE single technology appraisal. Pharmacoeconomics 2019;Epub ahead of print. Full text.

 

Forbes CFayter Dde Kock S, Quek RGW. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res 2019;11:2321-37Full text.

Forbes 2019 Appendix A
Forbes_2019_Cancer Management and Resear[...]
Adobe Acrobat document [446.2 KB]
Forbes 2019 Appendix B
Forbes_2019_Cancer Management and Resear[...]
Adobe Acrobat document [451.0 KB]
Forbes 2019 Appendix C
Forbes_2019_ Cancer Management and Resea[...]
Adobe Acrobat document [624.0 KB]

 

Majoie HJM, van Gaalen J, Verstegen DML, van Mastrigt GAPG, Kleijnen J, Alonso-Coello P, et al. Cost-conscious high-quality care and guideline development education: a strange contradiction or simple solution? Letter. Eur J Neurol 2019;26(4):e48-e49.

 

Hillemanns P, Friese K, Dannecker C, Klug S, Seifert U, Iftner T, Hädicke J, Löning T, Horn L, Schmidt D, Ikenberg H, Steiner M, Freitag U, Siebert U, Sroczynski G, Sauerbrei W, Beckmann MW, Gebhardt M, Friedrich M, Münstedt K, Schneider A, Kaufmann A, Petry KU, Schäfer APA, Pawlita M, Weis J, Mehnert A, Fehr M, Grimm C, Reich O, Arbyn M, Kleijnen J, Wesselmann S, Nothacker M, Follmann M, Langer T, Jentschke M. Prevention of cervical cancer: guideline of the DGGG and the DKG (S3 Level, AWMF register number 015/027OL, December 2017) - Part 1 with introduction, screening and the pathology of cervical dysplasia. Geburtshilfe Frauenheilkd 2019;79(2):148-59. Full text.

 

Hillemanns P, Friese K, Dannecker C, Klug S, Seifert U, Iftner T, Hädicke J, Löning T, Horn L, Schmidt D, Ikenberg H, Steiner M, Freitag U, Siebert U, Sroczynski G, Sauerbrei W, Beckmann MW, Gebhardt M, Friedrich M, Münstedt K, Schneider A, Kaufmann A, Petry KU, Schäfer APA, Pawlita M, Weis J, Mehnert A, Fehr M, Grimm C, Reich O, Arbyn M, Kleijnen J, Wesselmann S, Nothacker M, Follmann M, Langer T, Jentschke M. Prevention of cervical cancer: guideline of the DGGG and the DKG (S3 Level, AWMF register number 015/027OL, December 2017) - Part 2 on triage, treatment and follow-up. Geburtshilfe Frauenheilkd 2019;79(2):160-76. Full text.

 

Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S, PROBAST Group. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med 2019;170(1):51-58. Full text.

 

Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med 2019;170(1):W1-W33. Full text.